 |
市場調查報告書
商品編碼
2058362
新冠病毒治療市場：依藥物類別、給藥途徑、通路及地區分類Coronavirus Treatment Drugs Market, By Drug Class, By Route of Administration, By Distribution Channel, By Geography |
||||||
價格
簡介目錄
據估計，新冠病毒治療市場在2026年的價值為248億美元，預計到2033年將達到620億美元。預計從2026年到2033年，該市場將以13.3%的複合年成長率成長。
| 報告範圍 | 報告詳情 | ||
|---|---|---|---|
| 基準年： | 2025 | 2026年市場規模： | 248億美元 |
| 歷史數據時期： | 2020年至2024年 | 預測期： | 2026年至2033年 |
| 2026年至2033年預測期間的複合年成長率： | 13.30% | 2033年市場規模預測： | 620億美元 |
新冠病毒治療藥物是指用於治療新型冠狀病毒的藥物。用於治療冠狀病毒的藥物種類繁多，包括皮質類固醇、抗病毒藥物、單株抗體和激酶抑制劑。冠狀病毒的治療通常根據症狀的嚴重程度而定，從重度到中度再到輕度不等。冠狀病毒的常見症狀包括類似感冒的症狀、發燒、呼吸急促、頭痛和腹痛。
市場動態
各大公司正集中精力獲得產品核准，以鞏固其在全球新冠肺炎治療市場的地位。例如，2020年6月，印度製藥公司Glenmark Pharmaceuticals Limited推出了Fabiflu，這是第一個用於治療輕度至中度新冠肺炎患者的口服片劑。 Fabiflu為200毫克片劑，每片售價1美元。美國病患價格：一板34片售價47.55美元。
此外，領導企業正著力於非內生性成長策略，例如透過此類協議，來鞏固其在全球新冠肺炎治療市場的地位。例如，2020年9月，印度製藥公司瑞迪博士實驗室（Dr. Reddy's Laboratories）宣佈在印度市場推出瑞德西韋（remdesivir），品牌名為「Redyx」。 「Redyx」作為新冠肺炎治療藥物的上市是基於瑞迪博士實驗室與吉利德科學公司（Gilead Sciences Inc.）之間的許可協議。該協議授予瑞迪博士實驗室在包括印度在內的127個國家註冊、生產和銷售瑞德西韋作為新冠肺炎潛在治療藥物的權利。
本次調查的主要特點
- 本報告分析了全球新冠肺炎治療市場的現狀和未來潛力。新冠肺炎治療市場按藥物類別、給藥途徑、分銷管道和地區進行細分。
- 本報告對全球冠狀病毒治療市場進行了詳細分析，給出了預測期（2026-2033 年）的市場規模和複合年成長率（%）。
- 本報告揭示了各細分市場的潛在商機，並說明了該市場極具吸引力的投資提案矩陣。此外，報告還深入分析了市場促進因素、限制因素、機會、各國市場前景以及主要參與者所採取的競爭策略。
- 本報告根據以下參數對全球冠狀病毒治療市場的主要參與者進行了分析：公司概況、財務表現、產品系列、地理分佈、主要發展和未來計劃。
- 透過利用本報告中提出的見解，企業行銷負責人和經營團隊將能夠就未來的市場擴張和行銷策略做出明智的決策。
- 這份全球 COVID-19 治療市場報告旨在為行業內的各類相關人員提供參考，包括投資者、產品開發商和製造商、經銷商、醫療機構、研究機構、新參與企業和金融分析師。
- 相關人員將在決策過程中從全球 COVID-19 治療市場分析中使用的各種策略矩陣中受益匪淺。
目錄
第1章：研究目標與前提條件
- 分析目的
- 先決條件
- 簡稱
第2章 市場概覽
- 報告說明
- 市場定義和範圍
- 執行摘要
第3章：市場動態、監管與趨勢分析
- 市場動態
- 影響分析
- 主要亮點
- 監管趨勢
- 產品上市及核准
- PEST分析
- 波特的分析
- 市場機遇
- 監管趨勢
- 主要進展
- 產業趨勢
第4章 全球冠狀病毒治療市場：依藥物類別分類，2021-2033年
- 皮質類固醇
- 抗病毒藥物
- 單株抗體
- 激酶抑制劑
- 其他
第5章 全球冠狀病毒治療藥物市場：依給藥途徑分類，2021-2033年
- 口服
- 靜脈
第6章 全球冠狀病毒治療市場：依通路分類，2021-2033年
- 醫院藥房
- 零售藥房
- 網路藥房
第7章 全球冠狀病毒治療市場：依地區分類，2021-2033年
- 北美洲
- 美國
- 加拿大
- 拉丁美洲
- 巴西
- 阿根廷
- 墨西哥
- 其他拉丁美洲國家
- 歐洲
- 德國
- 英國
- 西班牙
- 法國
- 義大利
- 俄羅斯
- 其他歐洲國家
- 亞太地區
- 中國
- 印度
- 日本
- 澳洲
- 韓國
- ASEAN
- 其他亞太國家
- 中東
- 海灣合作理事會國家
- 以色列
- 其他中東國家
- 非洲
- 南非
- 北非
- 中非
第8章 競爭情勢
- Serum Institute of India
- Pfizer Inc.
- AstraZeneca plc.
- Bharat Biotech International Limited
- Cadila Healthcare Limited
- Johnson & Johnson
- Moderna
- GlaxoSmithKline plc
- CanSino Biologics
- Sinovac Biotech
- Novavax, Inc.
- Glenmark Pharmaceuticals Limited
- Dr. Reddy's Laboratories
- Merck & Co., Inc.
第9章 分析師建議
- 機會分析
- 分析師意見
- Coherent Opportunity Map
第10章 參考文獻與調查方法
- 參考
- 調查方法
- 關於本公司
簡介目錄
Product Code: CMI4312
Coronavirus Treatment Drugs Market is estimated to be valued at USD 24.8 Bn in 2026 and is expected to reach USD 62 Bn by 2033, growing at a compound annual growth rate (CAGR) of 13.3% from 2026 to 2033.
| Report Coverage | Report Details | ||
|---|---|---|---|
| Base Year: | 2025 | Market Size in 2026: | USD 24.8 Bn |
| Historical Data for: | 2020 To 2024 | Forecast Period: | 2026 To 2033 |
| Forecast Period 2026 to 2033 CAGR: | 13.30% | 2033 Value Projection: | USD 62 Bn |
The coronavirus treatment drugs comprises therapeutics which are used for treatment of the novel coronavirus. There are various drug classes such as corticosteroids, anti-viral, monoclonal antibodies, Kinase inhibitors which can be used for treatment of the coronavirus. The coronavirus is generally treated depending on severity of symptoms such as severe, moderate and mild. The common symptoms of coronavirus are cold, fever, breathlessness, headache, and stomach pain.
Market Dynamics
Key players are focusing on obtaining product approvals in order to strengthen their position in the global coronavirus treatment drugs market. For instance, in June 2020, Glenmark Pharmaceuticals Limited, a pharmaceutical company in India, launched the first orally administered tablet, Fabiflu, for the treatment of patients suffering from mild and moderate symptoms of COVID-19. Fabiflu is available as a 200 mg tablet, has been priced at US$ 1 per tablet. A strip of 34 tablets will cost US$ 47.55 to the patients in India.
Furthermore, key companies are focusing on inorganic strategies such agreements in order to strengthen their position in the global coronavirus treatments drugs market. For instance, in September 2020, Dr Reddy's Laboratories, an Indian pharmaceutical company, announced the launch of Remdesivir under the brand name, Redyx, for the Indian market. The launch of Redyx for treatment for COVID-19 is because of licensing agreement of Dr Reddy Laboratories with Gilead Sciences Inc. which grants Dr Reddy's Laboratories the right to register, manufacture and sell Remdesivir, as a potential treatment for COVID-19 in 127 countries including India.
Key features of the study
- This report studies the current scenario as well as the future potential of the global coronavirus treatment drugs market. The market for coronavirus treatment drugs is segmented on the basis of drug class, route of administration, distribution channel, and region.
- This report provides in-depth analysis of the global coronavirus treatment drugs market, and provides market size (US$ Mn) and compound annual growth rate (CAGR) (%) for the forecast period (2026-2033)
- It elucidates potential revenue opportunity across different segments and explains attractive investment proposition matrix for this market. It provides valuable insights about market drivers, restraints, opportunities, country outlook, and competitive strategies adopted by leading players.
- It profiles leading players in the global coronavirus treatment drugs market based on the following parameters - company overview, financial performance, product portfolio, geographical presence, key developments, and future plans.
- Insights from this report would allow marketers and management authorities of companies to make informed decisions with respect to future market expansion and marketing tactics
- The global coronavirus treatment drugs market report caters to various stakeholders in this industry, including investors, product developers and manufacturers, distributors, healthcare organizations, research institutes, new entrants, and financial analysts
- Stakeholders would greatly benefit in decision making through various strategy matrices used in analyzing the global coronavirus treatment drugs market.
Market Segmentation
- By Drug Class (Revenue, USD Bn, 2021-2033)
- Corticosteroids
- Anti-viral drugs
- Monoclonal Antibodies
- Kinase Inhibitors
- Others
- By Route of Administration (Revenue, USD Bn, 2021-2033)
- Oral
- Intravenous
- By Distribution Channel (Revenue, USD Bn, 2021-2033)
- Hospital Pharmacies
- Retail Pharmacies
- Online Pharmacies
- By Region (Revenue, USD Bn, 2021-2033)
- North America
- U.S.
- Canada
- Latin America
- Brazil
- Mexico
- Argentina
- Rest of Latin America
- Europe
- Germany
- U.K.
- France
- Italy
- Spain
- Russia
- Rest of Europe
- Asia Pacific
- China
- India
- Japan
- Australia
- South Korea
- ASEAN
- Rest of Asia Pacific
- Middle East
- GCC
- Israel
- Rest of Middle East
- Africa
- South Africa
- Central Africa
- North Africa
- Key Players
- Serum Institute of India
- Pfizer Inc.
- AstraZeneca plc.
- Bharat Biotech International Limited
- Cadila Healthcare Limited
- Johnson & Johnson
- Moderna
- GlaxoSmithKline plc.
- CanSino Biologics
- Sinovac Biotech
- Novavax, Inc.
- Glenmark Pharmaceuticals Limited
- Merck & Co., Inc.
- Reddy's Laboratories
Table of Contents
1. Research Objectives and Assumptions
- Research Objectives
- Assumptions
- Abbreviations
2. Market Overview
- Report Description
- Market Definition and Scope
- Executive Summary
- Global Coronavirus Treatment Drugs Market, By Drug Class
- Global Coronavirus Treatment Drugs Market, By Route of Administration
- Global Coronavirus Treatment Drugs Market, By Distribution Channel
- Global Coronavirus Treatment Drugs Market, By Region
3. Market Dynamics, Regulations, and Trends Analysis
- Market Dynamics
- Impact Analysis
- Key Highlights
- Regulatory Scenario
- Product Launches/Approvals
- PEST Analysis
- PORTER's Analysis
- Market Opportunities
- Regulatory Scenario
- Key Developments
- Industry Trend
4. Global Coronavirus Treatment Drugs Market, By Drug Class, 2021-2033, (USD Bn)
- Introduction
- Market Share Analysis, 2026 and 2033 (%)
- Y-o-Y Growth Analysis, 2022 - 2033
- Segment Trends
- Corticosteroids
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021-2033, (USD Bn)
- Anti-viral drugs
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021-2033, (USD Bn)
- Monoclonal Antibodies
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021-2033, (USD Bn)
- Kinase Inhibitors
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021-2033, (USD Bn)
- Others
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021-2033, (USD Bn)
5. Global Coronavirus Treatment Drugs Market, By Route of Administration, 2021-2033, (USD Bn)
- Introduction
- Market Share Analysis, 2026 and 2033 (%)
- Y-o-Y Growth Analysis, 2022 - 2033
- Segment Trends
- Oral
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021-2033, (USD Bn)
- Intravenous
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021-2033, (USD Bn)
6. Global Coronavirus Treatment Drugs Market, By Distribution Channel, 2021-2033, (USD Bn)
- Introduction
- Market Share Analysis, 2026 and 2033 (%)
- Y-o-Y Growth Analysis, 2022 - 2033
- Segment Trends
- Hospital Pharmacies
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021-2033, (USD Bn)
- Retail Pharmacies
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021-2033, (USD Bn)
- Online Pharmacies
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021-2033, (USD Bn)
7. Global Coronavirus Treatment Drugs Market, By Region, 2021 - 2033, Value (USD Bn)
- Introduction
- Market Share (%) Analysis, 2026 & 2033, Value (USD Bn)
- Market Y-o-Y Growth Analysis (%), 2022 - 2033, Value (USD Bn)
- Regional Trends
- North America
- Introduction
- Market Size and Forecast, By Drug Class, 2021 - 2033, Value (USD Bn)
- Market Size and Forecast, By Route of Administration, 2021 - 2033, Value (USD Bn)
- Market Size and Forecast, By Distribution Channel, 2021 - 2033, Value (USD Bn)
- Market Size and Forecast, By Country, 2021 - 2033, Value (USD Bn)
- U.S.
- Canada
- Latin America
- Introduction
- Market Size and Forecast, By Drug Class, 2021 - 2033, Value (USD Bn)
- Market Size and Forecast, By Route of Administration, 2021 - 2033, Value (USD Bn)
- Market Size and Forecast, By Distribution Channel, 2021 - 2033, Value (USD Bn)
- Market Size and Forecast, By Country, 2021 - 2033, Value (USD Bn)
- Brazil
- Argentina
- Mexico
- Rest of Latin America
- Europe
- Introduction
- Market Size and Forecast, By Drug Class, 2021 - 2033, Value (USD Bn)
- Market Size and Forecast, By Route of Administration, 2021 - 2033, Value (USD Bn)
- Market Size and Forecast, By Distribution Channel, 2021 - 2033, Value (USD Bn)
- Market Size and Forecast, By Country, 2021 - 2033, Value (USD Bn)
- Germany
- U.K.
- Spain
- France
- Italy
- Russia
- Rest of Europe
- Asia Pacific
- Introduction
- Market Size and Forecast, By Drug Class, 2021 - 2033, Value (USD Bn)
- Market Size and Forecast, By Route of Administration, 2021 - 2033, Value (USD Bn)
- Market Size and Forecast, By Distribution Channel, 2021 - 2033, Value (USD Bn)
- Market Size and Forecast, By Country, 2021 - 2033, Value (USD Bn)
- China
- India
- Japan
- Australia
- South Korea
- ASEAN
- Rest of Asia Pacific
- Middle East
- Introduction
- Market Size and Forecast, By Drug Class, 2021 - 2033, Value (USD Bn)
- Market Size and Forecast, By Route of Administration, 2021 - 2033, Value (USD Bn)
- Market Size and Forecast, By Distribution Channel, 2021 - 2033, Value (USD Bn)
- Market Size and Forecast, By Country, 2021 - 2033, Value (USD Bn)
- GCC Countries
- Israel
- Rest of Middle East
- Africa
- Introduction
- Market Size and Forecast, By Drug Class, 2021 - 2033, Value (USD Bn)
- Market Size and Forecast, By Route of Administration, 2021 - 2033, Value (USD Bn)
- Market Size and Forecast, By Distribution Channel, 2021 - 2033, Value (USD Bn)
- Market Size and Forecast, By Country, 2021 - 2033, Value (USD Bn)
- South Africa
- North Africa
- Central Africa
8. Competitive Landscape
- Serum Institute of India
- Company Highlights
- Product Portfolio
- Key Developments
- Financial Performance
- Strategies
- Pfizer Inc.
- Company Highlights
- Product Portfolio
- Key Developments
- Financial Performance
- Strategies
- AstraZeneca plc.
- Company Highlights
- Product Portfolio
- Key Developments
- Financial Performance
- Strategies
- Bharat Biotech International Limited
- Company Highlights
- Product Portfolio
- Key Developments
- Financial Performance
- Strategies
- Cadila Healthcare Limited
- Company Highlights
- Product Portfolio
- Key Developments
- Financial Performance
- Strategies
- Johnson & Johnson
- Company Highlights
- Product Portfolio
- Key Developments
- Financial Performance
- Strategies
- Moderna
- Company Highlights
- Product Portfolio
- Key Developments
- Financial Performance
- Strategies
- GlaxoSmithKline plc
- Company Highlights
- Product Portfolio
- Key Developments
- Financial Performance
- Strategies
- CanSino Biologics
- Company Highlights
- Product Portfolio
- Key Developments
- Financial Performance
- Strategies
- Sinovac Biotech
- Company Highlights
- Product Portfolio
- Key Developments
- Financial Performance
- Strategies
- Novavax, Inc.
- Company Highlights
- Product Portfolio
- Key Developments
- Financial Performance
- Strategies
- Glenmark Pharmaceuticals Limited
- Company Highlights
- Product Portfolio
- Key Developments
- Financial Performance
- Strategies
- Dr. Reddy's Laboratories
- Company Highlights
- Product Portfolio
- Key Developments
- Financial Performance
- Strategies
- Merck & Co., Inc.
- Company Highlights
- Product Portfolio
- Key Developments
- Financial Performance
- Strategies
9. Analyst Recommendations
- Wheel of Fortune
- Analyst View
- Coherent Opportunity Map
10. References and Research Methodology
- References
- Research Methodology
- About us
